ADSTILADRIN J Code: J9029

Drug & Product Overview

HCPCS Descriptor Intravesical instillation, nadofaragene firadenovec-vncg, per therapeutic dose

HCPCS Added Date July 1, 2023

Manufacturer Ferring Pharmaceuticals Inc

Route of Administration Intravesical

Generic Status Single-Source; Branded

Dosage Form Suspension

About ADSTILADRIN

Adstiladrin is a medication aligned to the HCPCS J Code: J9029 for billing, pricing, and reimbursement purposes in the United States. Classified under Oncology, it is administered via the intravesical route and manufactured by Ferring Pharmaceuticals Inc.

According to CMS Drug Use Information: This product is used to treat a certain type of cancer (bladder cancer). Nadofaragene firadenovec is made from a certain virus that has been specially prepared. The virus is used to carry a certain human gene (interferon alfa) into cells. This type of treatment is known as gene therapy.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. Showing 1 of 2 NDCs — log in for the full crosswalk.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
55566-1050-01	Adstiladrin	Ferring Pharmaceuticals Inc.	1	Adstiladrin Intravesic al Suspension 30… Login for More
•••••-••••-•• Log in to view	ADSTILADRIN

Login to view 1 more NDC package View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

ADSTILADRIN Pricing & Reimbursement

J9029 Private Payer Reimbursement

$65,614.48 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

ADSTILADRIN Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 42.82%

Avg. Days to File 15.6days

Avg. Days to Pay 42.4days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore J9029 claims analytics on FocalPoint →

ADSTILADRIN CPT Administration Codes

CPT Code	Description
51720	Bladder instillation of anticarcinogenic agent, including retention time

JW / JZ modifiers apply

CMS has identified Adstiladrin (J9029) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

ADSTILADRIN Medically Unlikely Edits (MUE)

The most billing units of J9029 Medicare will pay for one patient in one day, as published by CMS. 1 unit = per therapeutic dose.

Practitioner Office & Hospital Outpatient

1 unit / day

Same limit in both settings

MAI 2 · Date of Service Edit: Policy. Absolute per-day limit set by policy or regulation; units above it are not payable, and denials are not appealable on medical-necessity grounds. See all MUE limits →

ADSTILADRIN Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

BCG-unresponsive non–muscle invasive bladder cancer (carcinoma in situ, with or without papillary tumors)

Frequently Asked Questions

Is there a manufacturer-published billing and coding guide for Adstiladrin?

Billing and coding information for ADSTILADRIN can be found through Ferring Pharmaceuticals Inc. Visit Here →

Are there any available patient assistance programs for Adstiladrin?

ADSTILADRIN patient assistance information can be found through FERRING. Visit Here →

Where can I find Adstiladrin prescribing information?

Adstiladrin prescribing information can be found at the link below. Visit Here →

Is there available side effect information for Adstiladrin?

Side effect information for Adstiladrin can be found through Medline Plus at the link below. Visit Here →

Does billing ADSTILADRIN require JZ/JW wastage modifiers?

CMS has identified ADSTILADRIN(J9029) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.